Phase III Setback For Merck's Antithrombotic Damages One Of The Key Assets Of The Schering Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck does not yet know why DSMB decided no longer to study vorapaxar in stroke and ACS patients, but market analysts suspect a finding of excess bleeding.